Hospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (223)

2024

  1. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

  2. Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain

    REC: CardioClinics

  3. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  4. Embolization of percutaneous left atrial appendage closure devices: timing, management and clinical outcomes

    Cardiovascular Revascularization Medicine

  5. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo

    Science translational medicine, Vol. 16, Núm. 734, pp. eadg7962

  6. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

  7. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

  8. Platelet C3G: a key player in vesicle exocytosis, spreading and clot retraction

    Cellular and Molecular Life Sciences, Vol. 81, Núm. 1

  9. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  10. T-reg transcriptomic signatures identify response to check-point inhibitors

    Scientific Reports, Vol. 14, Núm. 1

  11. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2023

  1. Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 503-510

  2. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  3. Considerations for the clinical development of immuno-oncology agents in cancer

    Frontiers in immunology, Vol. 14, pp. 1229575

  4. Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217

  5. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  6. Iberian experience with PASCAL transcatheter edge-to-edge repair for mitral valve regurgitation

    Revista Espanola de Cardiologia, Vol. 76, Núm. 1, pp. 25-31

  7. Impact of Device Implant Depth After Left Atrial Appendage Occlusion

    JACC. Cardiovascular interventions, Vol. 16, Núm. 17, pp. 2139-2149

  8. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

    Cells, Vol. 12, Núm. 15

  9. Mast Cell Activation Syndromes: Comparison Between Two Scoring Models to Predict for Mast Cell Clonality

    The journal of allergy and clinical immunology. In practice, Vol. 11, Núm. 3, pp. 908-919